ArticleTurk pediatri arsivi2019
Behçet's disease in children: single-center experience.
Article in Turk pediatri arsivi, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Article
- Ocular Manifestations of Pediatric Behçet's Disease.Clinical medicine & research · 2025Review
- Article
- A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well-Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease.Immunity, inflammation and disease · 2024Article
- Vasculitis in Children.Turkish archives of pediatrics · 2024Review
- Clinical characteristics of pediatric noninfectious uveitis and risk factors for severe disease: a single-center study.Clinical rheumatology · 2024Article
- Uveitis in paediatric Behçet disease: a large multicentric Italian cohort.Therapeutic advances in musculoskeletal disease · 2024Article
- Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Pediatric Behçet's disease: Experience of a single tertiary center.Archives of rheumatology · 2023Article
- Paediatric Behçet's Disease: A Comprehensive Review with an Emphasis on Monogenic Mimics.Journal of clinical medicine · 2022Review
- Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network.Internal and emergency medicine · 2021Article
- Pediatric Behçet's Disease.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn this study, it was aimed to summarize the demographics, and clinical and laboratory findings of children who were diagnosed as having Behçet's disease, and also to determine the efficacy, duration, and adverse effects of the treatments. MATERIAL AND
methodsThe records of 34 patients who were diagnosed according to the International Behçet Study Group criteria between 1980 and 2013 in the Department of Pediatric Nephrology and Rheumatology, Hacettepe University Faculty of Medicine, were retrospectively reviewed and all demographic and clinical features were recorded. In the light of these data, the sex and age distribution, clinical and laboratory findings, most commonly preferred treatment approaches, efficacy of treatments, and adverse effects during treatment were analyzed.
resultsOf the 34 children with Behçet's disease, 18 (53%) were male and 16 (47%) were female, and the mean age was 11.18±3.34 years. There was no significant difference in age distribution of the male and female patients (p<0.05). In 97% (n=33) of the patients, the first symptom was recurrent oral aphthae. In order of frequency, the other mucocutaneous findings were pseudofoliculitis and pustular lesions (82%), genital ulcers (62%), and pathergy positivity (50%). System involvements in order of frequency were as follows: joint findings (38%), ocular findings (35%), vascular involvement (32%), neurologic involvement (18%), gastrointestinal involvement (5.8%), and pulmonary involvement (5.8%). Colchicine was the most commonly preferred drug (88%). Steroids were added to treatment in patients with skin involvement. Azathioprine was added in patients with uveitis. Anticoagulant therapy, cyclophosphamide, and anti-tumor necrosis factor-alpha were added in patients with vascular involvement. In patients with gastrointestinal system involvement, sulfasalazine was added to treatment. Diarrhea was the most common adverse effect in patients who used colchicine. In the patients who used steroid treatment, gastrointestinal symptoms such as unintentional weight gain, acne, and agitation were observed (17%). One patient who received interferon treatment had symptoms of depression and agitation.
conclusionThe aim of this study was to review the general characteristics of pediatric patients with Behçet's disease and to emphasize the importance of early diagnosis and correct treatment in terms of mortality and morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.